Exelixis: A Real Cabozantinib Cash Machine Pricing In an Unproven Second Act

Company vertical history

Origins and listing path

Exelixis began in 1994 as a discovery company built around model-system genetics. The company's own history page says the founding scientific vision was to use model-system genetics to systematize drug discovery, a very late-1990s way of thinking about biotech: platform first, commercial product later. By 2000 it had gone public on Nasdaq, selling 9.1 million shares at $13 and raising $118 million. In other words, Exelixis reached the market as a genomics-era research platform, not as a near-commercial specialty oncology company. That matters because the DNA of the company was set before the business model matured. It started life as a science engine and only later learned capital discipline the hard way.

The early business model was collaboration-heavy. Even at the end of 2000, Exelixis's year-end release described revenue growth as coming primarily from expanded collaborations with Bayer, Pharmacia, Bristol-Myers Squibb, and Dow AgroSciences. The company had funding, but not yet a self-owned commercial franchise. It looked like many platform biotechs of its era: broad scientific ambition, lots of partnered optionality, and no clear proof that one internal asset could carry the company economically.

A first important turn came in 2010 when Michael Morrissey replaced George Scangos as president and chief executive officer. Morrissey had been part of Exelixis since 2000 and knew the research engine from the inside. His tenure is central to the company's identity because it spans both the collapse and the recovery. It is common for a biotech to survive one of those. It is less common to survive both under the same chief executive and then become a disciplined capital return story.

The stages that shaped the current company

The first stage was the platform-and-partnership era. Exelixis was a research organization monetizing platform relevance through alliances. The capital-market narrative was still broad genomics optionality. That story fit the era, but it was not built to produce stable public-market compounding. Collaboration revenue could support research; it could not create the kind of durable valuation center that comes from a leading approved oncology medicine.

The second stage was the cabozantinib concentration bet. The company's first drug approval came with COMETRIQ in medullary thyroid cancer, but the real strategic wager was that cabozantinib could become much more than an orphan product. Exelixis poured itself into that thesis and nearly broke the company doing it. In 2014, cabozantinib failed in a phase 3 prostate-cancer study, and Exelixis responded with a restructuring that reduced the workforce by about 70 percent. This was not a routine setback. It was a near-existential narrowing of the business around the indications still worth funding. In hindsight, that crisis probably did more to define the modern Exelixis than the original IPO did. It turned the company from a many-shot, science-first biotech into a concentrated capital allocator obsessed with making one asset win.

The third stage was the franchise-building recovery. This began when Exelixis paired cabozantinib's remaining clinical potential with smarter operating and partnership choices. In 2016, Ipsen acquired rights outside the U.S. and Japan, paying Exelixis $210 million upfront; by the end of 2025 Exelixis had received $659.2 million in milestones from Ipsen and earned $837.9 million in royalties on Ipsen's sales. In 2017, Takeda took exclusive rights in Japan, paying $50 million upfront and subsequently contributing milestone and royalty revenue. These deals mattered for more than cash. They let Exelixis keep the U.S. profit pool while reducing the capital burden of building a global oncology field force on its own. That was a major institutional turn from the old platform-biotech model.

At the same time, cabozantinib's label and clinical relevance improved. Exelixis's 2025 annual report explicitly describes the cabozantinib story as having grown "from an orphan drug into a global oncology franchise" through approvals in multiple disease settings, therapy lines, and combinations with immunotherapy. That is not marketing fluff. The numbers behind it are hard. By 2025, U.S. cabozantinib franchise net product revenue reached $2.123 billion, up 17 percent year over year. The company's market identity had shifted from "biotech with a pipeline" to "commercial oncology company with a pipeline."

The fourth stage is the one investors are living through now: the handoff attempt. Exelixis entered 2025 and 2026 trying to do two things at once. First, it pushed CABOMETYX harder into NET, where its 2025 annual report says it became the leading oral therapy in the second-line-or-later setting. Second, it built zanzalintinib as a second franchise candidate, with the first commercial opportunity in third-line-or-later metastatic colorectal cancer. That is the current capital-market narrative in one sentence: defend and extend cabozantinib long enough to let zanzalintinib become real.

Key nodes that still matter today

The 2014 collapse still matters because it explains today's discipline. The current buyback-heavy, focus-driven Exelixis was forged in a period when the company had no choice but to prune. Investors should not romanticize that episode, but they should understand its legacy: management learned what happens when clinical ambition outruns financial reality.

The 2016 and 2017 partnership deals still matter because they shaped the economics of the franchise. Exelixis kept the U.S., where pricing and market share mattered most to valuation, while using Ipsen and Takeda to widen the molecule's cash reach. Even in the first quarter of 2026, Exelixis earned $45.9 million of royalty revenue based on cabozantinib sales generated by those partners. That is why the company's revenue stream is more durable than "one domestic drug" suggests, even though molecule concentration remains high.

The 2025 corporate reorganization is a smaller event, but it says something about management's posture. Exelixis recorded $19.8 million of restructuring expense in the third quarter of 2025 after deciding to reorganize the workforce and close the King of Prussia office, with total charges expected around $20.5 million. This was not distress. It was pruning around a stronger core while the company was still growing. The timing suggests management wanted the organization aligned behind Alameda operations and the next franchise push rather than carrying pandemic-era excess capacity into the zanzalintinib launch window.

The biggest current node is plainly the zanzalintinib colorectal-cancer filing. In February 2026, the FDA accepted the NDA for zanzalintinib plus atezolizumab in previously treated metastatic CRC and assigned a December 3, 2026 PDUFA date. The filing rests on STELLAR-303, where Exelixis says the combination improved overall survival versus regorafenib in the intention-to-treat population. This node genuinely can change the company's fate. Approval would not eliminate cabozantinib concentration overnight, but it would move Exelixis from "one major marketed franchise" to "one cash franchise plus one launching franchise." A complete response letter would leave the business intact but would materially damage the equity story because it would force the market to value Exelixis much more like a caboz-only cash harvester with a shortening exclusivity horizon.

Business model and industry

How the business really works

Exelixis reports as a single operating segment, but economically the revenue stack has three layers. The first is U.S. product revenue, overwhelmingly CABOMETYX, with a small tail from COMETRIQ. The second is ex-U.S. royalty and milestone income tied to the same molecule through Ipsen and Takeda. The third is collaboration revenue tied to development arrangements. In practice, the first layer dominates the story. For 2025, Exelixis booked $2.123 billion of U.S. cabozantinib franchise net product revenue against $2.320 billion of total company revenue. In the first quarter of 2026, net product revenue was $555.0 million and collaboration revenue was $55.8 million. That is concentration by any standard.

That concentration is both strength and weakness. It is strength because CABOMETYX is a real franchise with established prescriber behavior, not a launch still searching for a market. It is weakness because nearly every important line on the income statement still depends on the health, exclusivity, and competitive standing of one molecule. Exelixis has diversified the monetization paths of cabozantinib. It has not yet diversified away from cabozantinib.

The cost structure looks like what a good small-molecule oncology franchise ought to look like. COGS is low: 2026 guidance puts cost of goods sold at 3.5 percent to 4.5 percent of net product revenue. The harder costs to flex are R&D and commercial infrastructure, because the company is trying to preserve a launch-capable oncology organization and move multiple pivotal programs at once. That is why Exelixis can generate strong operating leverage and still keep R&D near $900 million. It has the margin structure of a mature commercial biotech and the spending profile of a company still trying to write its next chapter.

Real moats and weaker moats

The first real moat is clinical position inside specific tumor settings, especially RCC. CABOMETYX has survived long enough in hard oncology markets to qualify as more than a temporary winner. Exelixis's 2025 annual report says it ended 2025 as the most prescribed first-line TKI used with immunotherapy in RCC and the leading second-line TKI monotherapy. Those positions were not created by a single approval headline; they were built by line-extension strategy, comparator data, and prescriber familiarity over years. In oncology, that matters. Doctors do not switch stable treatment habits for style points.

The second real moat is commercialization know-how in tumor niches that are big enough to matter but specialized enough to reward focus. The NET launch is the best recent example. Exelixis went into 2025 with a new label expansion and, by its own year-end account, had already become the leading oral therapy in second-line-or-later NET. That suggests the company knows how to mobilize a focused sales and medical-affairs effort around a well-understood mechanism and a defined prescriber base. The moat here is not "brand" in the consumer sense. It is execution in specialty oncology channels.

The third real moat is capital structure. Exelixis can self-fund. At year-end 2025, cash, cash equivalents, and marketable securities totaled $1.663 billion. The company then kept buying back stock while holding 2026 R&D guidance near $900 million. Most oncology-biotech peers cannot do both. That matters because it lets Exelixis pursue a second franchise without serial dilution. It also gives the company bargaining power in business development because it does not have to transact from weakness.

The weaker moat is patent rhetoric. The 2025 10-K makes clear that cabozantinib does have later Orange Book-listed patents running into 2030-2033. It also makes clear that the original composition-of-matter patent expires in August 2026 and that multiple generic or alternative applicants are already litigating. Patent estates are real protections. They are not magic shields. Exelixis may well defend the franchise deep into the 2030 period. Investors should still treat exclusivity timing as contested, not fixed.

Industry structure and cycle

The background industry remains attractive. IQVIA says global cancer-medicine spending reached $252 billion at list prices in 2024 and could reach $441 billion by 2029. Growth is broad-based, but not dumb. It is being driven by both rising prevalence and the arrival of higher-value targeted and combination therapies, though later this decade biosimilar competition in PD-1 and PD-L1 classes should slow some of the headline growth. Exelixis participates in a good part of oncology: targeted therapy in tumors where line-of-therapy sequencing still creates room for specialized products.

The underlying disease burden supports that view. SEER estimates 80,450 new kidney and renal pelvis cancer cases in the U.S. in 2026, with 15,160 deaths. It also estimates 158,850 new colorectal-cancer cases and 55,230 deaths. Those are large, durable treatment pools. Neuroendocrine disease is smaller, but its incidence and prevalence have risen over long periods. Published analyses of SEER data show the age-adjusted incidence of NETs rising from 1.09 per 100,000 in 1973 to 6.98 in 2012, and more recent work reports continued increases in incidence and prevalence into 2021. For Exelixis, that means its core markets are not cyclical in the usual industrial sense. Demand is driven by diagnosis, survival, treatment sequencing, and standards of care, not by GDP swings.

So the relevant cycles are different. This is a defensive demand business, but it is exposed to a patent cycle, a regulatory cycle, a reimbursement cycle, and a technology-iteration cycle. The most important external variables are not commodity input costs or consumer confidence. They are guideline positioning, clinical readouts, FDA decisions, payer discount structures, and generic litigation. That is why Exelixis can look financially stable quarter to quarter and still carry significant permanent-capital risk if one of those variables breaks the wrong way.

Policy risk has become more tangible. Exelixis's 10-K and first-quarter 2026 10-Q both discuss the Inflation Reduction Act, the Medicare Drug Price Negotiation Program, and the Part D Manufacturer Discount Program. The company says its cabozantinib franchise qualified for the small-biotech exception through at least the 2028 price-applicability year and that it also qualified as a specified small manufacturer for phased-in Part D discounts from 2025 to 2031. That softens near-term pricing risk. It does not remove it. Exelixis also flagged uncertainty around most-favored-nation pricing proposals and even tariff risk on imported patented pharmaceuticals and ingredients. In other words, the demand curve is defensive, but the net realized price is becoming more political.

Horizontal competitor analysis

The comparison problem

Exelixis has many product competitors and only a few imperfect listed-company peers. That makes this a hybrid comparison case. If the question is "who directly competes for the same oncologist and patient?" the field is broad: RCC and NET are populated by large pharma regimens and niche oncology franchises, and colorectal cancer in later lines has its own entrenched standards. If the question is "which listed companies do investors use as reference points?" the answer is a mixed peer set that includes one profitable commercial biotech, such as Incyte, and several pipeline-premium oncology names, such as Revolution Medicines and Summit Therapeutics. The right way to compare Exelixis is to separate the customer battlefield from the capital-market battlefield.

The customer battlefield

In RCC, Exelixis is selling a clinician habit that has held, not a miracle. The company's own disclosures say CABOMETYX, whether used as the leading second-line TKI monotherapy or in first-line immunotherapy combinations, retained leadership positions through the end of 2025. That means competitors have not displaced it despite a crowded immuno-oncology environment. The threat now comes less from old VEGF-TKI combinations and more from the next sequencing wave, including Merck-linked belzutifan combinations reflected in LITESPARK studies and other evolving RCC regimens. Exelixis is trying to participate in that threat as well as defend against it, via collaboration with Merck.

In NET, the attraction of CABOMETYX is different. Exelixis's message is that it has become the leading oral option in second-line-or-later settings, which matters because oral targeted therapies compete on efficacy and safety, clinician familiarity, and sequencing convenience. The company has already built a commercial beachhead here. The question is durability. NET is fruitful for Exelixis precisely because it is a narrower market where focused commercialization works. It is also risky for the same reason: a change in guideline preference or a stronger targeted competitor can take real share from a focused franchise faster than from a sprawling mass market.

In third-line metastatic CRC, Exelixis is still a challenger. STELLAR-303 used regorafenib as the comparator, which tells you what the company is trying to displace first. An approval in December would not move Exelixis into a blue-ocean market. It would move the company into one of the most difficult launch settings in oncology: late-line colorectal cancer, where physicians are used to incremental benefit and reimbursement scrutiny is tight. This is why the first commercial opportunity for zanzalintinib matters, but not in a simplistic "approval equals victory" way. Approval would create a beachhead. The harder test would be real uptake.

The capital-market battlefield

The table below is deliberately narrow. It compares current public-market positioning, not business quality by itself.

Table source: real-time market data from July 16, 2026 UTC.

The business reason behind those numbers is revealing. Incyte is more diversified and much larger by revenue base. It reported $5.14 billion of total 2025 revenue, more than double Exelixis's $2.320 billion. Yet Incyte's earnings multiple is slightly lower. The market is effectively telling you that diversification is worth something, but not everything, and that Exelixis's nearer-term growth and event optionality deserve a moderate premium.

Revolution Medicines and Summit sit on the other side of the spectrum. They are not being valued on current P/E because there is no useful current P/E to value. They are being valued on pipeline imagination, trial timing, and the possibility of category-defining assets. Exelixis trades far below those narrative valuations because it is already a real business. That is a discount, but it is also protection. A profitable oncology company with established cash flow can disappoint and remain solvent. A pure pipeline premium can halve on one bad chart.

That leads to Exelixis's ecological niche. It is a challenger in oncology products, but a hybrid in public markets: more speculative than a plain specialty-pharma cash harvester, less speculative than a pre-revenue oncology bet. The hole it fills is useful for investors. It offers direct exposure to oncology growth and clinical catalysts without the existential financing risk that comes with most single-asset biotech stories. The hole it must now defend is just as clear. If zanzalintinib stumbles, the market will stop giving Exelixis the benefit of that hybrid identity and will drag it closer to mature-franchise math.

Current fundamentals and valuation

Financial vertical review

A compact financial history captures the shape of Exelixis better than a long chronology.

Table source: Exelixis 2025 Form 10-K.

The business meaning is clear. Growth came primarily from price-and-volume resilience in CABOMETYX, then from the NET expansion, not from accounting gains or acquisition rollup. The margin profile improved because this is a high-gross-margin small-molecule oncology business and because Exelixis did not allow operating cost growth to swallow all of the added revenue. Yet management did not run the business for maximum short-term margin. It reinvested heavily, which is why the right way to read Exelixis is not "look how high earnings got," but "look how much earnings it can produce while still funding almost $900 million of annual R&D."

Cash conversion has been better than accounting earnings. Over the last three full years presented side by side in the 2025 10-K, operating cash flow was 1.60x net income in 2023, 1.34x in 2024, and 1.13x in 2025. That is healthy. The decline in the ratio reflects a business becoming larger and more normalized, not one losing control of working capital. Capex is tiny, so owner earnings are close to operating cash flow. Even if I conservatively deduct all reported capex rather than trying to split maintenance from growth, 2025 owner earnings were roughly $876 million. That places the stock on an owner-earnings yield of roughly 6.2 percent against a market cap of about $14.1 billion, versus a headline earnings yield of about 5.6 percent. The gap is meaningful, but nowhere near large enough to overturn the basic P/E framing.

Balance-sheet quality remains a strength. Cash, cash equivalents, and marketable securities stood at $1.663 billion at year-end 2025, down from $1.749 billion one year earlier largely because Exelixis spent nearly $948 million on repurchases in 2025. That is an important distinction. The balance sheet shrank because management returned capital and funded development, not because the core business consumed cash.

Price and valuation history

Since listing, Exelixis has gone through at least five market identities. It began as a genomics-era platform name after the 2000 IPO. It then became a clinical-optionality biotech around cabozantinib. It became a distressed and doubted survivor after the 2014 prostate-cancer failure and restructuring. It rerated into a commercial oncology growth story as RCC approvals and the Ipsen/Takeda monetization structure proved durable. More recently, it has traded as a second-franchise setup with buyback support.

The lesson in that history is that Exelixis's multiple has moved with earnings, and with what kind of company investors think it is. Today's valuation sits in the middle ground. Macrotrends shows a historical P/E around 18.9x in mid-July 2026. That is not deep value. It is also not a platform-mania multiple. The market is treating Exelixis as a good biotech with a real business and a contested next act. That label feels broadly correct.

What is happening now

First-quarter 2026 results were strong enough to reinforce the existing story, but not extreme enough to change it. Revenue rose to $610.8 million from $555.4 million a year earlier. Net product revenue rose to $555.0 million on higher sales volume. GAAP net income increased to $210.5 million from $159.6 million, with diluted EPS climbing to $0.79 from $0.55, helped by lower share count after repurchases. Management maintained 2026 total-revenue guidance at $2.525 billion to $2.625 billion and R&D guidance at $875 million to $925 million. That revenue guidance explicitly excludes any U.S. revenue from a potential zanzalintinib colorectal-cancer launch.

The strongest operating message was that cabozantinib still had momentum despite its maturity. Exelixis said on the 2025 annual report and subsequent 2026 commentary that CABOMETYX remained the leading TKI in RCC and the leading oral therapy in second-line-or-later NET. Secondary transcript coverage of the first-quarter call also stated that management described quarter-high record new-patient starts for CABOMETYX. I treat that latter point as a management statement rather than an independently audited metric, but it is directionally consistent with the revenue print.

The market is therefore trading three linked variables at once. The first is whether CABOMETYX can stay healthier for longer than the bear case allows. The second is whether December 2026 produces an FDA approval for zanzalintinib in CRC. The third, and more subtle one, is whether Exelixis can convert an approval into the beginnings of a repeatable franchise playbook. That third variable gets less attention because it is less dramatic than a PDUFA headline. Over a three- to five-year period, it is probably the most important.

Bull and bear divergence

The bull case rests on four pieces of evidence. CABOMETYX is still gaining or defending clinically relevant share in RCC and has already established a meaningful position in NET, which is why revenue kept rising even before any zanzalintinib contribution. Exelixis converts earnings to cash and can finance both pivotal R&D and large buybacks internally. The zanzalintinib NDA in CRC is based on overall-survival improvement versus regorafenib, not on a softer surrogate endpoint alone. And the company's partnership model lets it access broader development programs without shouldering every cost itself.

The bear case also rests on hard facts. Exelixis remains overwhelmingly dependent on cabozantinib economically. The original composition-of-matter patent expires in August 2026, and generic litigation is active across several later patents. The company has not yet independently proven that zanzalintinib can become a durable commercial franchise beyond the first CRC filing. And the public disclosures around STELLAR-316 still described the trial as "planned" in May 2026, while the company's July 2026 clinical-trials page did not list it among active pivotal studies, which suggests initiation had not yet been clearly confirmed by the research date. That last point does not break the thesis, but it does matter because investors are already paying for a future broader franchise, not one NDA.

Valuation analysis

Historical valuation does not rescue the stock. Exelixis's mid-July 2026 P/E around 18.9x is moderate compared with narrative biotech extremes, but it is not low for a company carrying this degree of single-molecule concentration and regulatory binary risk. Against profitable peer Incyte at roughly 16.3x, Exelixis carries a small premium. Against pre-revenue oncology names with negative earnings, Exelixis is much cheaper. The market is paying for quality and event optionality, but not paying bubble prices.

This is the place to state the expectation gap plainly. The current stock price appears to assume that CABOMETYX remains durable through the late 2020s and that zanzalintinib has a credible path to becoming at least one meaningful marketed product line. It does not appear to price a full, broad, platform-level success across every pivotal study. By the same token, it also does not price a regulatory failure cleanly enough to leave much valuation protection. The market is halfway committed. That is why the stock feels reasonable rather than attractive.

The absolute valuation below uses owner-earnings logic first and then translates that into scenario values. Because Exelixis's capex is tiny, owner earnings are close to operating cash flow after full capex deduction. 2025 owner earnings were roughly $876 million. This is valuation-scenario analysis within a research framework, not investment advice.

Scenario basis: owner-earnings approach anchored in 2025 cash conversion, 2026 guidance, and current market multiples.

Those scenario values lead to a simple conclusion. Exelixis already trades above the conservative value, which means the margin of safety is not present on that frame. It still offers decent upside if the base case unfolds, but the expected return is neither so high nor so skewed that investors have to chase it today. The stock is priced like a solid business with a real catalyst, which is exactly what it is.

The margin-of-safety recheck is not flattering. Against conservative value, the current price carries no discount. The most fragile assumption in the base case is the market's willingness to capitalize a successful approval into a credible second-franchise narrative, not CABOMETYX's current health. If I haircut the base-case growth and launch contribution to about 70 percent, the implied value falls from roughly $63 to roughly $57. If earnings were simply flat around current owner-earnings power for the next three years and the multiple did not rerate upward, annualized return would sit in the low single digits, below the roughly 4.55 percent yield available on the U.S. 10-year Treasury on July 15, 2026. On that test, there is no margin of safety at this buy price.

Margin-of-safety sufficiency verdict: not obvious.

Risks, catalysts, and tracking dashboard

The biggest business risk is concentration risk. If CABOMETYX weakens structurally in RCC or NET before zanzalintinib is commercially established, the company has no second product large enough to absorb the shock. Probability is medium; impact is high. The observable indicators are U.S. net product revenue growth, share commentary in RCC and NET, and any signs of payer pressure or guideline repositioning.

The largest external risk is patent-and-generic risk. Exelixis's later cabozantinib patents still run into the 2030-2033 period, but legal challenges are already active. Probability is medium; impact is high. The transmission path is direct: a negative court development would compress both revenue expectations and the valuation multiple at once.

The key franchise-building risk is regulatory and launch execution around zanzalintinib. Probability of some form of delay is always medium in oncology; impact here is high because the market is using zanzalintinib to justify part of Exelixis's premium to plain cash-cow math. Observable indicators are the December 3, 2026 FDA outcome, early launch commentary if approved, and confirmation that follow-on pivotal studies such as STELLAR-316 have actually started.

The valuation risk is quieter but real. Exelixis is not expensive enough to collapse on style rotation alone, but it is expensive enough that a rise in rates or a broad derating of biotech-event names would cap upside fast. That matters because current upside in the base case is moderate rather than huge. Probability is medium; impact is medium. The transmission path is multiple compression before any fundamental break.

The policy risk is lower probability in the near term but still worth tracking. IRA-related rebate changes and Medicare pricing mechanisms already affect net product revenue and could become more material over time. Probability is medium over a multiyear horizon; impact is medium. The signal is any loss of small-biotech exception status, tougher Part D economics, or more concrete MFN-style reimbursement actions.

Positive catalysts are easy to identify. The cleanest is an FDA approval for zanzalintinib in CRC on or before the PDUFA date. The second is evidence that CABOMETYX can continue to grow despite age and litigation overhang. The third is further proof that Exelixis can widen its franchise map through additional pivotal progress such as nccRCC, NET, or confirmed initiation of adjuvant CRC work. Negative catalysts are the mirror image: a CRL or major delay, a visible slowdown in CABOMETYX growth, an adverse patent ruling, or evidence that broader pivotal activity is slipping from management's stated cadence.

Dashboard source note: company releases, company event calendar, market-data services, and Treasury-yield sources. Google Finance showed a July 27, 2026 call date, Investing.com showed August 5, 2026, while Exelixis's own event calendar had not yet posted a second-quarter results event as of the research date. I therefore treat the next earnings date as unconfirmed.

Key data tables

Table source: Exelixis first-quarter 2026 results.

This quarter mattered because it showed the present business still improving before any zanzalintinib launch contribution. That is the foundation under the stock. Without it, the December catalyst would be a pure biotech lottery ticket. With it, the catalyst sits on top of a profitable base.

Research uncertainties

There are four material blind spots in this report.

First, I could verify that STELLAR-316 was described as "planned" in May 2026, but I could not verify a clear later company disclosure confirming that enrollment had started by July 16, 2026. The omission of STELLAR-316 from the July 2026 pipeline page supports the inference that the trial had not yet been clearly activated, but that remains an inference, not a definitive company statement.

Second, market services conflicted on the next earnings date, and Exelixis had not yet posted its own second-quarter 2026 results event. That affects the tracking dashboard, not the business thesis, but it is still a live uncertainty.

Third, I relied on current and historical market-data services for the July 2026 market-cap reference, because the company obviously does not publish daily market cap. That is standard practice, but the exact figure can vary slightly by source and timestamp.

Fourth, the sharpest valuation swing in Exelixis will come from the market's view of zanzalintinib launch quality after any approval. That is inherently not yet knowable from public information as of the research date.

Sources

Primary sources used most heavily in this report were Exelixis SEC filings and investor-relations materials, especially the 2025 Form 10-K, the Q1 2026 10-Q and earnings release, the 2025 annual report, the May 2026 Merck collaboration release, and the corporate pipeline page. Supporting industry and market context came from SEER, the American Cancer Society, IQVIA, FRED and Treasury market sources, plus selected financial-market data services for current valuation context.

Cross-synthesis summary

The capability Exelixis has genuinely proven over its whole journey is narrower than a full "platform winner" story but more valuable than that narrower description sounds. It has proven that it can take one internally important molecule, survive a near-fatal clinical failure around it, reshape the organization, secure partner economics that preserve the best part of the value stream, and then build a durable commercial franchise around that asset in oncology. That is a demanding skill set. It combines scientific judgment, organizational stamina, and capital allocation discipline. Many biotech companies prove one of those and fail at the others. Exelixis proved them in sequence.

Its past success was not merely an era tailwind. Oncology spending has been strong, yes, and targeted therapy remains an attractive industry. But if tailwind alone explained Exelixis, the company would not have needed a 70 percent workforce reduction in 2014 after the prostate-cancer failure. The recovery came from management narrowing the story to what could win, preserving the U.S. economics of cabozantinib, and extending the franchise into the exact disease settings where clinical relevance and commercialization execution could compound on each other. Luck had a role, as it always does in oncology development. Survival and rerating came from focus.

Those success factors are partly still present. Management still has cash, still has oncology-commercial infrastructure, still has a molecule that matters, and still has partners willing to co-fund parts of development. What is missing is proof of repeatability. Exelixis has not yet shown that it can launch a second major internally led oncology brand and make investors stop thinking in terms of a single-molecule dependency. That is the central reason the stock is only moderately attractive at current levels. Investors are being asked to pay for the possibility of repeatability rather than for repeatability already delivered.

Horizontally, Exelixis's greatest advantage over pipeline-premium peers is obvious: it can afford its own ambition. Revolution Medicines and Summit Therapeutics may be valued more richly on narrative, but they do not have Exelixis's cash-generation cushion today. Against diversified profitable biotech peers such as Incyte, Exelixis's advantage is different: it has a cleaner, more concentrated clinical-and-commercial rerating path if zanzalintinib works. Its weakness versus Incyte is exactly the same concentration. One company is harder to torpedo with one molecule's debt to time. The other is more capable of surprising to the upside if one event changes the franchise map.

That is why the current valuation feels like a judgment on both past and future. The market is rewarding past success by giving Exelixis a respectable earnings multiple and by accepting that large-scale buybacks are not reckless. But it is also pre-spending some future success. It is not pricing Exelixis as though December 2026 must be a home run. It is pricing the company as though a credible second act is more likely than not. I think that is a fair broad expectation, but not a cheap one.

What the market is most likely to misjudge right now is the difference between approval risk and business-building risk. The headline trade is the December 3, 2026 PDUFA date. The deeper trade is whether Exelixis can compound from there. If the FDA approves zanzalintinib, the first reaction may be to assume the strategic transition is underway and mostly solved. That would be too fast. The real proof would come from launch execution, reimbursement acceptance, and whether adjacent trials keep moving on time. If the FDA does not approve it, the reverse risk appears: the market could value Exelixis too harshly as though all forward optionality disappeared. That would also be too fast, because the CABOMETYX franchise still throws off real cash. The business is sturdier than the event. The stock, however, will still trade the event.

Over one year, the critical variables are the FDA decision, the early shape of any zanzalintinib launch, and whether CABOMETYX can still post resilient top-line growth. Over three years, the crucial variables are broader franchise proof: outcomes in nccRCC and NET, progress on new study starts, and continued patent defense. Over five years, the question becomes even simpler: whether Exelixis is still basically a cabozantinib company with appendages, or has become a true two-franchise oncology company with a replenishing pipeline behind it. Only the second answer deserves a structurally higher valuation center.

The conditions under which Exelixis becomes a better investment are equally simple. One path is price: if the stock falls into the low-40s without any fundamental break in CABOMETYX durability or zanzalintinib probability, the risk-reward improves sharply. The other path is proof: if the company wins FDA approval, shows real early uptake, confirms STELLAR-316 and other pivotal cadence cleanly, and the stock is still only around present levels, then the business would be less risky even if the price were not much cheaper. Three developments would overturn the current judgment: a clear adverse patent development that pulls expected caboz exclusivity materially forward; a CRC regulatory miss that is not offset by stronger data elsewhere; or two consecutive quarters showing CABOMETYX no longer has the share and volume resilience management is selling today.

Bull and bear reasons

• Exelixis generated $2.123 billion of 2025 U.S. cabozantinib franchise revenue, $884.3 million of operating cash flow, and only $8.4 million of capex, giving it unusual self-funded flexibility for a biotech of this size.

• CABOMETYX still held leadership positions in RCC and second-line-or-later NET through the end of 2025, which is rare commercial durability in a crowded oncology field.

• The FDA accepted the zanzalintinib CRC filing with a December 3, 2026 PDUFA date based on overall-survival benefit versus regorafenib in STELLAR-303.

• Ipsen and Takeda add royalties, milestones, and development-cost sharing, letting Exelixis preserve U.S. economics without fully funding global expansion alone.

• Exelixis is still economically concentrated around cabozantinib, with virtually all product revenue coming from the same molecule.

• The original cabozantinib composition-of-matter patent expires in August 2026, and multiple generic challengers are already attacking later patents.

• STELLAR-316 was still described as planned in May 2026 and was not listed among active pivotal studies on the July 2026 pipeline page, which weakens confidence in the breadth-and-timing part of the second-franchise story.

• At the current price, Exelixis trades above conservative value and offers a flat-earnings return below the July 2026 U.S. 10-year Treasury yield, so valuation is not providing protection.

Pre-mortem

One plausible 50 percent-down script runs through the FDA. In December 2026, the FDA issues a complete response letter or demands more work on the zanzalintinib CRC filing. Exelixis enters 2027 with CABOMETYX still profitable, but now the market treats the company as a single-franchise story moving toward a litigated patent boundary. Normalized owner earnings stay around $3.5 to $3.7 per share, but the multiple compresses from roughly 18x toward 11x to 12x because the market no longer pays for a second act. That points to a stock in the high 30s to low 40s, roughly 30 percent to 40 percent below the current level, and could be worse if the setback spills into confidence around later studies.

A harsher script runs through both competition and patents. Between 2027 and 2028, belzutifan-based RCC sequencing improves, CABOMETYX share growth stops, and one or more caboz patent challenges break badly enough to make earlier generic entry feel plausible. Exelixis keeps spending heavily on development because it still needs to build beyond caboz, so margins compress rather than self-heal. The market then values the business at 10x to 12x declining earnings instead of mid-to-high teens on stable earnings. In that scenario, the stock could trade into the upper 20s to low 30s. That is the path to a 50 percent drawdown from today.

Final research conclusion

Exelixis is a good business built on a narrow foundation. That is the right place to start. The company has a real oncology franchise, real cash generation, and a management team that has already navigated one boom-bust-rebuild cycle better than most biotech leadership teams ever manage. Those are serious positives. The reason I do not land on a more aggressive stance is price. The market is already giving Exelixis credit for being more than a fading single-product story, and some of that credit is deserved. It is also asking investors to underwrite a second-franchise transition before the transition has fully happened.

At the current price, the stock looks closer to fair than cheap. Approval of zanzalintinib in CRC would matter, but it would not by itself settle the long-term question. The bigger issue is whether Exelixis can repeat its cabozantinib playbook in a new franchise and keep the broader pivotal cadence on track while defending the existing moat from patent and regimen pressure. What worries me most is not bankruptcy, dilution, or balance-sheet stress. It is a softer but more important problem: a business durable enough to survive, but not cheap enough to protect shareholders if the handoff from cabozantinib to zanzalintinib is slower, narrower, or messier than today's market expects.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: high
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: Exelixis is a strong oncology cash generator, but today's price already assumes a credible handoff from CABOMETYX to zanzalintinib.
• 【Ideal Buy Price】40–50 USD
• Basis: at least a 20 percent discount to conservative value, which assumes cabozantinib durability but no successful 2026 zanzalintinib handoff.
• Acceptable hold price: 54–72 USD
• Clearly overvalued price: 87 USD and above
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes; the cleaner buy setup is either a pullback into the low-40s with CABOMETYX still intact, or a de-risked post-approval launch period with the stock still near current levels; the opportunity cost of waiting is missing a fast relief rally on a clean December approval.
• Target holding horizon: 1–3 years
• Expected annualized return: conservative about -4 percent; base about +4 percent; optimistic about +12 percent
• Max-loss risk: roughly 45 percent to 55 percent if zanzalintinib fails to launch, CABOMETYX growth fades, and the market rerates Exelixis toward mature-franchise patent-risk math
• Reassessment-trigger signals:
  • CABOMETYX U.S. net product revenue turns flat or negative for two consecutive quarters
  • an adverse patent ruling materially weakens Exelixis's later cabozantinib Orange Book defenses
  • the FDA issues a CRL or materially restrictive label outcome on the zanzalintinib CRC filing
  • STELLAR-316 still lacks clear initiation confirmation by the end of 2026
  • 2026 R&D spend runs above guidance without correspondingly stronger pivotal progress

【Valuation Range】

• current: 55.75 (close as of 2026-07-15)
• bear (conservative · ideal buy zone): [40, 50]
• base (fair · acceptable hold zone): [54, 72]
• bull (optimistic · above the clearly-overvalued line): [87, 95]

Other tickers mentioned

• INCY.US: closest profitable commercial-biotech peer for diversification and valuation comparison
• JAZZ.US: cash-generating specialty-biotech reference point for capital-allocation contrast
• RVMD.US: oncology pipeline-premium peer showing how the market prices pre-commercial optionality
• SMMT.US: binary oncology-development peer valued mainly on future clinical upside
• MRK.US: collaborator on belzutifan and pembrolizumab studies, and a strategic force in RCC treatment evolution
• BMY.US: co-markets nivolumab with CABOMETYX and competes across RCC combinations
• PFE.US: important RCC comparator through the Inlyta franchise
• NVS.US: benchmark NET competitor through everolimus and radioligand therapies

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.